Tests LBL-024 combination drug in people with metastatic colorectal cancer
Tests LBL-024 with other drugs in adults with colorectal cancer that has spread.
Plain-language title generated from the registry record
Registry title: A Clinical Trial of LBL-024 Combination Drug in Patients With Metastatic Colorectal Carcinoma
Key facts
- Where
- Chengdu, Guangzhou, Guilin, Jinan, Luoyang, Nanchang, Nanning, Shanghai, and Tianjin, ChinaSee the 10 sites
- Phase
- Phase 1/2
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults aged 18 to 75 with metastatic colorectal cancer. It tests LBL-024 together with other cancer drugs.
- Age
- 18 to 75 years
- Sex
- All sexes can join.
- Disease stage
- Metastatic colorectal cancer, with at least one measurable tumour lesion. ECOG performance score of 0 to 1.
- Earlier treatment
- No live vaccine within 4 weeks before the first dose.
Main reasons for not taking part
- Pleural effusion, pericardial effusion or ascites that cannot be controlled or needs repeated drainage
- Pregnancy or breastfeeding
- Active autoimmune disease
- Active hepatitis B or hepatitis C
- Immunodeficiency, including a positive HIV antibody test
Read by machine on 9 November 2026.
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 75 years old?
Source: NCT07791758, who can take part
Where in China
- Sichuan Cancer HospitalChengdu, ChinaNot yet recruiting
- Sun Yat-sen University Cancer CenterGuangzhou, ChinaTaking people
- The Sixth Affiliated Hospital, Sun Yat-sen UniversityGuangzhou, ChinaNot yet recruiting
- The First Affiliated Hospital of Guilin Medical UniversityGuilin, ChinaNot yet recruiting
- Shandong Cancer HospitalJinan, ChinaNot yet recruiting
- The First Affiliated Hospital of Henan University of Science &TechnologyLuoyang, ChinaNot yet recruiting
- The First Affiliated Hospital of NanChang UniversityNanchang, ChinaNot yet recruiting
- Guangxi Medical University Cancer HospitalNanning, ChinaNot yet recruiting
- Shanghai GoBroad Cancer HospitalShanghai, ChinaNot yet recruiting
- Tianjin Medical University Cancer Institute & HospitalTianjin, ChinaNot yet recruiting
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- Nanjing Leads Biolabs Co.,Ltd
- Trial code
- NCT07791758
- Record updated
- 16 October 2026
- Original description
This study is an open-label, multi-center Phase Ib/II clinical trial evaluating the safety and efficacy of LBL-024 in combination with other drugs for the treatment of metastatic colorectal carcinoma (mCRC), aiming to evaluate the safety and efficacy of LBL-024 in combination with other drugs in the treatment of mCRC patients.Read full original descriptionShow less
An Open-label, Multicenter Phase Ib/II Study to Evaluate the Safety and Efficacy of LBL-024 Combination Therapy in Patients With Metastatic Colorectal Carcinoma
This study is an open-label, multi-center Phase Ib/II clinical trial evaluating the safety and efficacy of LBL-024 in combination with other drugs for the treatment of metastatic colorectal carcinoma (mCRC), aiming to evaluate the safety and efficacy of LBL-024 in combination with other drugs in the treatment of mCRC patients.
Inclusion: Agree to follow the trial treatment regimen, visit schedule, laboratory test, and other requirements of the protocol, and voluntarily enroll in the study and sign the written informed consent; Age 18-75 years (inclusive of boundaries) at the time of signing informed consent form; The Eastern Cooperative Oncology Group's physical status scoring standard (ECOG) is 0~1; The expected survival time is at least 12 weeks; According to the evaluation of RECIST 1.1 （Response Evaluation Criteria in Solid Tumours），the Participants enrolled have at least one measurable lesion; There is adequate organ and bone marrow function,Conforms to laboratory test results; Male of childbearing potential and Females of childbearing age are willing to take highly effective contraceptive measures From the signing of the informed consent form to within 6 months after the last administration of the trial drug.
Exclusion: Subjects who received a live vaccine within 4 weeks prior to the first dose or are scheduled to receive a live vaccine during the study treatment period and within 4 weeks after the last dose; Participants with mental illness (impairing understanding or ability to give informed consent),history of Drug abuse, alcoholism or drug addiction; participant had a history of severe cardiovascular and cerebrovascular disorder; patients with active,Or patients who have had and may recur autoimmune diseases; patients with active hepatitis B or active hepatitis C; History of immunodeficiency including HIV antibody test positive; The investigator believes that the subject has other conditions that may affect compliance or are not suitable for participating in this study; Participants with clinically uncontrollable pleural effusion, pericardial effusion, ascites, and those requiring repeated drainage or medical intervention; Women during pregnancy or lactation.